{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:52:22Z","timestamp":1761630742470},"reference-count":25,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:p> Objectives - Anemia is the most common hematological alteration in patients with Crohn's disease, and is frequently related to intestinal inflammatory activity. Its cause is multifactorial and mostly associated with absolute iron deficiency (iron deficiency anemia) and\/or functional iron deficiency (inflammation anemia or anemia of chronic disease). It may also be identified through other causes, such as folic acid or vitamin B12 deficiency and secondary to adverse effects from medications (salicylic derivatives and immunosuppressive drugs). In the present study, patients with active Crohn's disease and anemia were evaluated and treated with intravenous ferric carboxymaltose. We discuss the therapeutic schemes (doses), safety, results and improvement of quality of life.  Methods - In the present prospective study, 10 consecutive patients with Crohn's disease, with moderate to severe activity, with anemia (Hb: 6.7 to 10 g\/dL), who were attended between March 2014 and March 2015, were evaluated. Six (60%) were men and four were women, all with moderate or severe anemia (hemoglobin &lt;10 g\/dL). They were treated with a maximum of three intravenous infusions of 1000 mg of ferric carboxymaltose, of at least 15 minutes in duration. It was also sought to correlate the inflammatory Crohn's disease activity degree (measured using the Crohn's Disease Activity Index, CDAI) and C-reactive protein level with the severity of anemia. The primary outcome was an increase in Hb of \u22652 g\/dL and the secondary outcome was the normalization of anemia (Hb \u226512 g\/dL for women and \u226513 g\/dL for men) and the improvement in quality of life seen 12 weeks after the last application of carboxymaltose.  Results - Among the 10 patients studied, parenteral iron supplementation was administered in three cases during hospitalization and the others received this on an outpatient basis. The total iron dose ranged from 1,000 to 2,000 mg, with an average of 1,650 mg. Crohn's disease activity measured using CDAI and C-reactive protein correlated with the intensity of anemia. An increase of 2 g\/dL occurred in eight (80%) patients after 12 weeks and normalization of anemia was found in seven (70%) patients. Improvements in quality-of-life scores were found for all (100%) patients after 12 weeks. Carboxymaltose was well tolerated. Three patients presented adverse reactions (two with nausea and one with headache) of mild intensity.  Conclusions - Anemia is a frequent complication for Crohn's disease patients. Intravenous iron therapy has been recommended for Crohn's disease patients, because for these patients, oral iron absorption is very limited. This is because of the inflammatory state and \"blocking\" of iron entry into enterocytes through hepcidin action on ferroportin, along with the elevated rates of gastrointestinal adverse events that compromise adherence to treatment and possibly aggravate the intestinal inflammatory state. The degree of Crohn's disease activity, as measured using CDAI and C-reactive protein, correlates with the severity of anemia. Carboxymaltose is a safe drug, which can be administrated in high doses (up to 1,000 mg per application per week) and corrects anemia and iron stocks over a short period of time, with consequent improvement in quality of life.<\/jats:p>","DOI":"10.1590\/s0004-28032015000400002","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T18:30:10Z","timestamp":1454178610000},"page":"255-259","source":"Crossref","is-referenced-by-count":11,"title":["TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose"],"prefix":"10.1590","volume":"52","author":[{"given":"Carlos Walter","family":"SOBRADO","sequence":"first","affiliation":[{"name":"Hospital 9 de Julho,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo Delfini","family":"CAN\u00c7ADO","sequence":"additional","affiliation":[{"name":"Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Faraco","family":"SOBRADO","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Onofre","family":"FRUGIS","sequence":"additional","affiliation":[{"name":"Hospital 9 de Julho,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel Faraco","family":"SOBRADO","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"25","key":"ref1","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker SD","year":"2009","journal-title":"N Engl J Med"},{"issue":"28","key":"ref2","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.3748\/wjg.v11.i28.4396","article-title":"Effects of iron manipulation on trace elements level in a model of colitis in rats","volume":"11","author":"Barollo M","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"2","key":"ref3","first-page":"199","article-title":"Prevalence and pathogenesis of anemia in inflammatory bowel disease","volume":"95","author":"Bergamaschi G","year":"2010","journal-title":"Influence of anti-tumor necrosis factor-Alfa treatment. Haematologica"},{"issue":"3","key":"ref4","first-page":"439","article-title":"Deveolopment of a Crohn's disease activity \u00edndex. National cooperative Crohn's disease study","volume":"70","author":"Best WR","year":"1976","journal-title":"Gastroenterology"},{"key":"ref5","series-title":"Manifesta\u00e7\u00f5es hematol\u00f3gicas na inflammatory bowel disease. In Inflammatory bowel disease","first-page":"135","author":"Can\u00e7ado RD","year":"2015"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled Trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev R","year":"2011","journal-title":"Gastroenterology"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/gut.2003.035758","article-title":"Iron, anaemia, and inflammatory bowel diseases","volume":"53","author":"Gasche C","year":"2004","journal-title":"Gut"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ibd.20285","article-title":"Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases","volume":"13","author":"Gasche C","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt G","year":"1989","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease","volume":"106","author":"Irvine EJ","year":"1994","journal-title":"Gastroenterology"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1052-5157(02)00006-5","article-title":"Upper gastrointestinal tract endoscopy in inflammatory bowel disease","volume":"12","author":"Isaacs KL","year":"2002","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"1-3","key":"ref12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.febslet.2004.07.081","article-title":"Tumour necrosis factor a regulates iron transport and transporter expression in human intestinal epithelial cells","volume":"573","author":"Johnson D","year":"2004","journal-title":"FEBS Lett"},{"issue":"11-12","key":"ref13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1365-2036.2006.03146.x","article-title":"Systematic review: manging anaemia in Crohn's disease","volume":"24","author":"Kulnigg S","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1572-0241.2007.01744.x","article-title":"A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial","volume":"103","author":"Kulnigg S","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/ndt\/gfn653","article-title":"Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)","volume":"24","author":"Locatelli F","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00005176-198905000-00004","article-title":"Crohn's disease lesion in the upper gastrointestinal correlation between clinical, radiological, endoscopic, and histological features in adolescents and children","volume":"8","author":"Mashako MN","year":"1989","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2036.2001.00930.x","article-title":"Iron and inflammatory bowel disease","volume":"15","author":"Oldenburg B","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2002-01-0136","article-title":"Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-a antibody therapy","volume":"100","author":"Papadaki HA","year":"2002","journal-title":"Blood"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2006.09.041","article-title":"Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption","volume":"127","author":"Qiu A","year":"2006","journal-title":"Cell"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00005176-199408000-00007","article-title":"Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn's disease","volume":"19","author":"Ruuska T","year":"1994","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/01.mib.0000235097.86360.04","article-title":"Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation","volume":"12","author":"Semrin G","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000275286.03283.18","article-title":"Intravenous ferric carboxymaltose compared with oral iron in the treatment of post-partum anemia: a randomized controlled trial","volume":"110","author":"Van Wyck DB","year":"2007","journal-title":"Obstet Gynecol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","article-title":"Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterinu bleeding: a randomized, controlled Trial","volume":"49","author":"Van Wyck DB","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3324\/haematol.2009.017046","article-title":"Pathogenesis and treatment of anemia in inflammatory bowel disease","volume":"95","author":"Weiss G","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.MIB.0000196646.64615.db","article-title":"Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients","volume":"12","author":"Wells CW","year":"2006","journal-title":"Inflamm Bowel Dis"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v52n4\/0004-2803-ag-52-04-00255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T06:02:01Z","timestamp":1495519321000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032015000400255&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0004-28032015000400255"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032015000400002","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}